Physician profile
Michael Venincasa
NPI 1790728178
$1,294.66
in general payments reported to CMS, 2019-2025
22 companies · $24.02 in 2025
The $24.02 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $117 · 2021: $195 · 2024: $98.05 · 2025: $24.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $227.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $212.69 | 2019-2021 | |
| Amgen INC. | $204.00 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $119.96 | 2019-2021 | |
| Sight Sciences, INC. | $98.05 | 2024 | Omni Surgical System |
| E.R. Squibb & Sons, L.L.C. | $53.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $52.24 | 2019-2021 | |
| Pfizer INC. | $40.15 | 2019 | |
| Biotronik INC. | $32.05 | 2019 | |
| Esperion Therapeutics, INC. | $31.01 | 2020 | |
| Astellas Pharma US INC | $30.02 | 2019 | |
| Merck Sharp & Dohme LLC | $28.31 | 2021 | |
| Sun Pharmaceutical Industries INC. | $24.02 | 2025 | |
| Akcea Therapeutics, INC. | $21.21 | 2019 | |
| Abbott Laboratories | $18.80 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $17.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.31 | 2019 | |
| Amarin Pharma, INC. | $16.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.29 | 2021 | |
| Medtronic, INC. | $13.39 | 2021 | |
| Cook Medical LLC | $12.33 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Venincasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.